
    
      PRIMARY OBJECTIVES:

      I. Evaluate the biodistribution and safety of [18F]FP-R01-MG-F2 in healthy volunteers.

      II. Evaluate the feasibility of [18F]FP-R01-MG-F2 PET/CT scanning in patients with pancreatic
      cancer.

      OUTLINE:

      Patients receive [18F]FP-R01-MG-F2 intravenously (IV) and undergo PET/CT or PET/MR scan
      immediately after and at 60 and 120 minutes. Patients will be followed up at 24-48 hours.
    
  